Grant to aid cancer treatment research

RUTLEDGE-FOUNDATION-WEB
Laura Rutledge and Dr. Andras Lacko

An experimental vaccine gave Carley Rutledge the chance to live a full life after Ewing’s sarcoma nearly took it away when she was 15.

Now 20, she’s a college student studying conservation biology and chemistry.

The same positive outlook could one day be shared by other young adult cancer survivors thanks to research being conducted at UNT Health Science Center. A $60,000 grant from the Rutledge Foundation is helping Dr. Andras Lacko, Professor of Physiology and Pediatrics, further his research on a drug-carrying delivery system that targets and destroys cancer cells. The hope is that this novel approach will one day be used to treat Ewing’s sarcoma.

The Lipoprotein Cancer Therapeutics lab, which recently opened at UNTHSC, will provide Dr. Lacko with more space and a larger staff to further his research in developing a way to use “good cholesterol” nanoparticles to selectively destroy tumors.

“It’s clear that cancer is an extremely complex disease, and the cells have many unique properties,” he said. “We want to see if find a better treatment with nanoparticles for this type of cancer.”

Over 30 years there has been little improvement in the treatment of Ewing’s sarcoma, said Laura Rutledge, the Foundation’s executive director and Carley’s mother.

“They basically give these kids as much chemo as they can tolerate before it kills them,” she said. “The lack of improvement in therapies and dangerous side effects is what drove me to start the Foundation.”

The non-profit organization funds immune-based targeted therapies because that is where the future of cancer treatment lies, Mrs. Rutledge said.

“Dr. Lacko’s research appealed to us because he’s using a natural process in the body as a vehicle for chemo so it goes straight to cancer without harming other cells,” she said.

The drug delivery method being studied by Dr. Lacko is anticipated to spare patients from the harmful effects of chemotherapy. He is studying ovarian and prostate cancer and now Ewing’s sarcoma.

“We are very fortunate to get this support,” he said. “It allows us to continue doing what we believe will be helpful in the treatment of cancer.”

Recent News

Stephanie Ibekwe
  • Our People
|Dec 5, 2022

A voice for women in medicine

When Dr. Stephanie Ibekwe’s mother, Sarah, came home from her nursing job, she would tell her daughter stories about her patients and the conversations she had with them. “Nursing is pretty stressful, but my mom had an amazing way of handling things,” she said. “My mom really loved to bui...
Noah Peeri Headshot
  • Our People
|Dec 5, 2022

SPH alum Dr. Noah Peeri produces JAMA Oncology publication just months after graduation

Noah Peeri, Ph.D., MPH, a recent graduate of The University of North Texas Health Science Center’s School of Public Health, has achieved a major milestone by publishing an article in the Journal of the American Medical Association Oncology just months after completing his graduate degree.   H...
Techstars Demo Day.
  • On Campus
|Dec 1, 2022

Techstars Demo Day brings innovation to the historic stockyards

For the last 13 weeks, the founders of 10 of the world’s most innovative startups have been in Fort Worth perfecting their new physical health technology. They are part of the world’s first physical health accelerator, and now they are ready to show the fruits of their labor. Techstars Demo D...
Dr. Sid O'bryant Award
  • Our People
|Dec 1, 2022

HSC named the winner of the D Magazines 2022 Achievement in Medical Research Award

The extensive research done by Dr. Sid O’Bryant and his team at the Institute of Translational Research has earned the University of North Texas Health Science Center at Fort Worth the 2022 Medical Research Award by D Magazine. Dr. O’Bryant, the executive director of the ITR and a professor at t...